William D. Linn

519 total citations
17 papers, 389 citations indexed

About

William D. Linn is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Geriatrics and Gerontology. According to data from OpenAlex, William D. Linn has authored 17 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 4 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Geriatrics and Gerontology. Recurrent topics in William D. Linn's work include Blood Pressure and Hypertension Studies (4 papers), Diabetes Treatment and Management (3 papers) and Pharmaceutical Practices and Patient Outcomes (3 papers). William D. Linn is often cited by papers focused on Blood Pressure and Hypertension Studies (4 papers), Diabetes Treatment and Management (3 papers) and Pharmaceutical Practices and Patient Outcomes (3 papers). William D. Linn collaborates with scholars based in United States, Switzerland and South Korea. William D. Linn's co-authors include Cynthia D. Mulrow, Henry I. Bussey, Jacqueline A. Pugh, Laurajo Ryan, Rebecca L. Attridge, Christopher R. Frei, Theresa Bianco, Lisa Farnett, Elaine Chiquette and Maura A. Kraynak and has published in prestigious journals such as The American Journal of Cardiology, Journal of General Internal Medicine and American Journal of Hypertension.

In The Last Decade

William D. Linn

17 papers receiving 353 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William D. Linn United States 11 119 57 56 45 39 17 389
Frits R. Rosendaal Netherlands 3 100 0.8× 43 0.8× 19 0.3× 33 0.7× 43 1.1× 4 373
Arthur A. Schuna United States 13 54 0.5× 66 1.2× 49 0.9× 22 0.5× 33 0.8× 19 573
M J Peake Australia 14 59 0.5× 77 1.4× 11 0.2× 68 1.5× 30 0.8× 33 722
Sonja Gandhi Canada 14 112 0.9× 122 2.1× 79 1.4× 51 1.1× 50 1.3× 21 845
Richard S Slavik Canada 14 121 1.0× 88 1.5× 105 1.9× 31 0.7× 13 0.3× 31 531
James A. Visconti United States 13 102 0.9× 65 1.1× 85 1.5× 24 0.5× 65 1.7× 39 636
Stephanie D. Schech United States 8 60 0.5× 140 2.5× 33 0.6× 25 0.6× 61 1.6× 12 469
Tone Westergren Norway 7 35 0.3× 80 1.4× 21 0.4× 19 0.4× 27 0.7× 19 332
P. A. de Graeff Netherlands 16 349 2.9× 52 0.9× 24 0.4× 90 2.0× 29 0.7× 27 594
Gary J. Okano United States 13 95 0.8× 47 0.8× 300 5.4× 29 0.6× 36 0.9× 22 698

Countries citing papers authored by William D. Linn

Since Specialization
Citations

This map shows the geographic impact of William D. Linn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William D. Linn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William D. Linn more than expected).

Fields of papers citing papers by William D. Linn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William D. Linn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William D. Linn. The network helps show where William D. Linn may publish in the future.

Co-authorship network of co-authors of William D. Linn

This figure shows the co-authorship network connecting the top 25 collaborators of William D. Linn. A scholar is included among the top collaborators of William D. Linn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William D. Linn. William D. Linn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Attridge, Rebecca L., et al.. (2013). Fenofibrate-associated nephrotoxicity: A review of current evidence. American Journal of Health-System Pharmacy. 70(14). 1219–1225. 47 indexed citations
2.
Ip, Eric J., et al.. (2012). A Mnemonic for Pharmacy Students to Use in Pharmacotherapy Assessment. American Journal of Pharmaceutical Education. 76(1). 16–16. 3 indexed citations
3.
Attridge, Rebecca L., William D. Linn, Laurajo Ryan, Jim M. Koeller, & Christopher R. Frei. (2011). Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. Journal of clinical lipidology. 6(1). 19–26. 18 indexed citations
4.
Vincze, G, et al.. (2008). Use of antihypertensive medications among United States veterans newly diagnosed with hypertension. Current Medical Research and Opinion. 24(3). 795–805. 5 indexed citations
5.
Wen, Lonnie, Michael L. Parchman, William D. Linn, & Shuko Lee. (2004). Association between Self-Monitoring of Blood Glucose and Glycemic Control in Patients with type 2 Diabetes Mellitus. American Journal of Health-System Pharmacy. 61(22). 2401–2405. 12 indexed citations
6.
Kraynak, Maura A., et al.. (1998). Effects of Marine Fish Oils on the Anticoagulation Status of Patients Receiving Chronic Warfarin Therapy. Journal of Thrombosis and Thrombolysis. 5(3). 257–261. 41 indexed citations
7.
Bussey, Henry I., Elaine Chiquette, Theresa Bianco, et al.. (1997). A Statistical and Clinical Evaluation of Fingerstick and Routine Laboratory Prothrombin Time Measurements. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(5). 861–866. 34 indexed citations
8.
Zabalgoitia, Miguel, et al.. (1997). Use of dobutamine stress echocardiography in assessing mechanical aortic prostheses: comparison with exercise echocardiography.. PubMed. 6(3). 253–7. 11 indexed citations
9.
Lewin, Andrew, et al.. (1997). Long‐Acting Diltiazem CD Is Safe and Effective in a Hypertensive Mexican‐American Population. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(6). 1254–1259. 7 indexed citations
10.
Carmichael, Jannet M., Mary Beth O’Connell, Beth Devine, et al.. (1997). Collaborative Drug Therapy Management by Pharmacists. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(5). 1050–1061. 55 indexed citations
11.
Zabalgoitia, Miguel, Syed N. Rahman, William E. Haley, et al.. (1997). Disparity Between Diastolic Mitral Flow Characteristics and Left Ventricular Mass in Essential Hypertension. The American Journal of Cardiology. 79(9). 1255–1258. 12 indexed citations
12.
Rahman, Syed N., William E. Haley, Steven A. Yarows, et al.. (1996). Gender dimorphism in cardiac adaptation to hypertension is unveiled by prior treatment and efficacy. The American Journal of Cardiology. 78(7). 838–840. 12 indexed citations
13.
Linn, William D.. (1996). Angiotensin‐Converting Enzyme Inhibitors in Left Ventricular Dysfunction. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 16(2P2). 50S–58S. 6 indexed citations
14.
Bianco, Theresa, et al.. (1992). Potential Warfarin‐Ciprofloxacin Interaction in Patients Receiving Long‐Term Anticoagulation. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 12(6). 435–439. 44 indexed citations
15.
Linn, William D., et al.. (1989). Captopril-Stimulated Renin Secretion in the Diagnosis of Renovascular Hypertension. American Journal of Hypertension. 2(5_Pt_1). 335–340. 7 indexed citations
16.
Mulrow, Cynthia D., et al.. (1989). Assessing quality of a diagnostic test evaluation. Journal of General Internal Medicine. 4(4). 288–295. 68 indexed citations
17.
Hersh, Marla R., William D. Linn, John G. Kuhn, & Daniel D. Von Hoff. (1986). Electrocardiographic monitoring of patients receiving phase I cancer chemotherapy.. PubMed. 70(3). 349–52. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frits R. Rosendaal Breakdown of academic impact, for papers by Arthur A. Schuna Breakdown of academic impact, for papers by M J Peake Breakdown of academic impact, for papers by Sonja Gandhi Breakdown of academic impact, for papers by Richard S Slavik Breakdown of academic impact, for papers by James A. Visconti Breakdown of academic impact, for papers by Stephanie D. Schech Breakdown of academic impact, for papers by Tone Westergren Breakdown of academic impact, for papers by P. A. de Graeff Breakdown of academic impact, for papers by Gary J. Okano
Rankless by CCL
2026